Nufoss Biosciences and Hodder Biosciences will jointly develop cell treatments for ophthalmic diseases based on human induced pluripotent stem cells

Newforth Biotechnology Co.
, Ltd.
is a leading biomedical company that develops AAV gene therapy for ophthalmic diseases, and Hodder Bioengineering Co.
, Ltd.
is a biomedicine with a leading human induced pluripotent stem cell (iPSC) and neural cell differentiation technology platform Company
.

Today the two companies jointly announced that they will reach a strategic partnership to cooperate in the development of human iPSC-derived cell products for the treatment of eye diseases

This cooperation combines Newforth's experience in global gene/cell therapy drug development, a deep understanding of eye diseases, and Hodder's advantages in the GMP production and quality system of human iPSC-derived clinical cell products, and it is expected to provide new A generation of treatment methods for eye diseases
.

Based on the terms of this cooperation, HODBio will obtain advance payment and milestone payment for the development of candidate cell products for retinal degenerative diseases, and Newforth has the right to obtain the exclusive authorization of the candidate product and is responsible for the clinical development of the product.

"This cooperation reflects the long-term goal of Newforth in the development of ophthalmic treatment methods.
We will continue to expand and develop the pipeline of innovative ophthalmic drug candidates," said Professor Li Bin, co-founder and chairman of Newforth.
"Induction Pluripotent stem cell iPSC is a very promising technology, which will play a huge potential in regenerative therapy, disease modeling and drug screening
.

"

Dr.
Fan Jing, founder and CEO of Hodder, said, “We are very happy to be able to cooperate with Nuvos this time
.

The human iPSC cell line we developed is made by transforming the skin of healthy donors into pluripotent stem cells through our own patents.

       "IPSC technology is expected to overcome retinal degenerative diseases that cannot be treated by AAV-mediated gene therapy," said Dr.
Yingming Lu, CEO of Newforth.
"Holder Bio is one of the most respected pioneers in the field of human iPSC translational medicine.
1.

We are very confident that Hodder's accumulation of technology and expertise in iPSC and targeted differentiation, combined with Newforth's experience in the field of ophthalmology and drug development, will jointly unlock a new generation of gene/cell innovative treatment methods for patients
.

"

       About Newforth

       Newforth is China's first gene therapy company for eye diseases
.

Newforth is headquartered in Wuhan, and has branch offices in Shanghai, Suzhou and the United States at the same time

       ABOUT HOD BIO

       Hodder Bioengineering Co.
, Ltd.
is one of the earliest human induced pluripotent stem cell therapy companies in China
.

Hodder was established in January 2017 by neuroscientists and stem cell biologists from Hopkins University in Hangzhou, China and Baltimore, USA